• Red White & Bloom released its Q4 2020 and FY 2020 results and later reported its Q1 2021 results
• In its Q4 2020 results, the company posted a 158% quarter-over-quarter increase in revenue from $CA6.1 million in Q3 2020 to $15.7 million
• Its FY revenue grew from nil in 2019 to CA$23.3 million in 2020, while its gross profit was CA$13.35 million in 2020 from nil in 2019
• RWB reported $32.7 million in Q1 2021 adjusted sales, an increase of 14.5% over Q4 2020

In a statement contained in the company’s December 2020 investor deck presentation, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) CEO Brad Rogers observed that multiple deals, “judiciously purchased and diligently structured,” were all coming together to create “the most exciting times in the history of the company.” He further noted that the company was looking to build on its key assets focusing on growing the bottom line for its shareholders (https://cnw.fm/kjuF0).

Red White & Bloom recently made two announcements that show its progress thus far and perhaps tell of the dawn of the exciting times. On July 22, the company announced its Q4 2020 and full-year results (https://cnw.fm/Pt9xt).

RWB reported a 158% quarter-over-quarter increase in revenue from CA$6.1 million in Q3 2020 to CA$15.7 million in Q4 2020. The company attributes this increase to the impact of the acquisition the Platinum Premium Cannabis Products (“PV”) on its balance sheet, given that Q4 2020 was the first full quarter post-closing. RWB’s revenue for the year ended December 31, 2020, grew to CA$23.3 million from nil in 2019, while its gross profit for the FY 2020 was CA$13.35 million, or 57% of the FY revenue, compared to nil in 2019.

Red White & Bloom closed FY 2020 having made significant strides as it seeks to be the superior and most recognizable cannabis company in the United States. It completed two transformative acquisitions: PV, which is licensed in California and has products being sold in Oklahoma and Michigan, and Mid-American Growers (“MAG”), a company that owns a 3.6-million-square-foot, state-of-the-art technology and science facility that will enable RWB to attain premium value for the products it wishes to cultivate.

The company has also raised more than US$110 million since January 1, 2020, which it expects will support its expansion and operations. Additionally, as of July 2, 2021, it had about CA$41 million cash on hand.

The company reports adjusted sales for the 1st quarter of $32.7 million, a sequential increase of 14.5% from the prior quarter’s adjusted sales of $28.6 million in Q4 2020. The increase was reduced by the strengthening Canadian dollar and would have been about $1 million higher using a constant dollar comparison (https://cnw.fm/BljZA).

“This was another great quarter for the company as we continued to see strong traction for our brands,” said Brad. “We are building on that momentum and working towards finalizing our revised asset purchase of our Michigan investee to bring their revenue, as well as adjusted sales into IFRS revenue format before the end of this current quarter.”

Once this is complete and the expansion of its Florida operations starts bearing fruits, the company expects to finally report in its quarterly results the strength of its accomplishments so far. As such, more is still to come for Vancouver-based Red White & Bloom as it positions itself to be one of the top three multi-state operators in the United States in cannabis and hemp-derived product lines.

For more information, visit the company’s website at www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Earlier in June, Andries Rossouw of PwC Africa Mining released a statement noting that during the peak of the coronavirus pandemic, mining companies with higher environmental, social and governance (“ESG”) ratings surpassed the broader market to deliver a 34% average total shareholder return, which is 10 points higher than the general market index. Companies  with higher ESG ratings are showing stronger long-term performance in market and shareholder value, as they continue to attract premiums on low-carbon inputs and benefit from capital access at lower interest rates.

This data was obtained from the annual review of the top-40 mining companies compiled by PwC, which examines the global trends in the mining industry. The review includes companies such as Gold Fields, AngloGold Ashanti, Impala Platinum, Sibanye Stillwater and Anglo American.

In the presentation, Rossouw also revealed that market capitalization rose by almost two-thirds to $1.46 trillion, while cash on hand increased by 40% and net profit in the sector grew by 15%.

Copper was found to be the exceptional performer in the metals group, as it contributed about $120 billion to group revenue. The average price of copper is expected to grow by 40% this year, based on consensus data. Additionally, the demand for iron ore is expected to grow, aided by national infrastructure initiatives whose objective is to help economies recover from the impact of the coronavirus.

Forecasts also indicate that the top-40 firms will report the second-highest net profit and record-high earnings and revenue before amortization, depreciation and taxes. This is in addition to showing that the demand for the minerals used in clean-energy technologies will increase sixfold in the next 20 years. In his conclusion, Rossouw notes that it is clear that investors focused on the sector will continue to be drawn to firms that actively embrace ESG policies.

The same can be said for tax transparency, which is an important ESG metric. It affords mining companies the chance to call attention to their significant financial contributions to their communities and the improvements in quality of life, infrastructure and education. Suppliers, governments, communities, employees and customers all expect companies to create sustainable value, which is why mining organizations should embrace tax transparency as part of their ESG strategy. This approach will help support the mining sector and encourage it to be more transparent about the rents and taxes they pay as well as the social benefits their contributions deliver.

For companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) that are operating in the global uranium extraction segment, adherence to ESG standards is even more important given the specialized applications in which uranium is put to use.

NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Scientists from the Cancer Research UK Cambridge Institute have designed tests that can detect the presence of a type of brain tumor known as a glioma via a patient’s blood plasma or urine. The group notes that this test is the first of its kind globally, adding that its results, which only included a handful of patients, are promising. The research is currently in its early stages and was published in “EMBO Molecular Medicine.”

Brain tumor recurrence in individuals who have already had a brain tumor removed is high, which is why monitoring patients using an MRI scan is important. Often, physicians also conduct biopsies in addition to performing the scan.

Blood tests that help detect various types of cancer have been a major focus for researchers around the globe. These tests are primarily based on identifying cell-free DNA, which is mutated DNA that is shed by tumor cells when they perish. However, the detection of brain tumor cell-free DNA in the blood has been challenging because of the blood-brain barrier.

This barrier separates blood from the cerebrospinal fluid (“CSF”), which surrounds the spinal cord and brain, hindering the passage of cells and particles like cell-free DNA. This is why the researchers, led by Dr. Richard Mair of the University of Cambridge and Dr. Florent Mouliere of the Rosenfeld Lab at the Cambridge institute, helped develop a pair of approaches that could be used to overcome the difficulties of detecting brain tumor cell-free DNA.

The first of the two approaches works for patients who have undergone brain tumor removal and biopsy. The researchers developed a tumor-guided sequencing test whose purpose was to identify mutations found in the tumor tissue in the patient’s blood plasma, cerebrospinal fluid and urine.

For this approach, the researchers discovered that it was possible to identify mutations even in minute amounts of cell-free DNA in the urine and blood plasma. Of the eight patients who were studied under this approach, the researchers were able to detect cell-free DNA in their urine, blood plasma and cerebrospinal fluid samples.

The second approach involved the scientists looking for other patterns in cell-free DNA that could indicate a tumor’s presence, without identifying the mutations. For this approach, they conducted an analysis of samples obtained from 26 healthy individuals, 27 patients with nonmalignant brain conditions and 35 glioma patients.

Using genome sequencing, they discovered fragments of cell-free DNA in both urine and blood samples, noting that the fragments that came from brain tumor patients were different in size in comparison with those from patients who didn’t have tumors.

The scientists propose that in the future, these tests could be used to monitor patients who have a high risk of brain tumors; this method would be more convenient in comparison to undergoing an MRI every three months, which is the current monitoring method.

As screening and testing for brain cancers is being improved, so are advancements being made in the quest to improve treatment. For example, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is developing organ-targeted therapeutics that, once approved, will offer better clinical outcomes to patients.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• American Academy of Neurology warns of critical neurologist shortfall amid increased incidence of brain disorders
• Brain Scientific addresses issue with portable, cost-effective brain diagnostic solutions that record EEGs in nearly any setting
• Product development includes creation of AI and ML algorithms to detect seizures, dementia and other brain-related conditions
• NeuroCap and NeuroEEG device patents approved in U.S., Europe and China

With a goal of addressing the current acute neurologist shortfall in the United States (https://ibn.fm/DrxvC), Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, has developed cost-effective and portable proprietary medical devices that are positioned to disrupt the electroencephalogram (“EEG”) market.

According to a report from the American Academy of Neurology 2019 Transforming Leaders Program, nearly every U.S. state is experiencing a neurologist shortfall amid an increase in neurological disorders (https://ibn.fm/DrxvC). Experts warn that access to high-level care and diagnosis is immediately required to reduce mental disability, improve patient outcomes and increase the wellbeing of the current pool of neurologists facing quality of life issues.

As part of the effort to address the shortfall, Brain Scientific aims to support the industry with the introduction of cost-effective, disposable brain diagnostic solutions that include the NeuroCap(TM) and NeuroEEG(TM). These portable devices are part of the company’s expanded vision for neurology telemedicine, allowing practitioners to collect diagnostic information quickly, upload it to cloud-based infrastructure, and leverage artificial intelligence (“AI”) and machine learning (“ML”) algorithms to detect seizures, dementia and other brain-related conditions.

Brain Scientific’s go-to-market strategy emphasizes relationships with leading hospitals, in addition to prioritizing the creation of partnerships with industry leaders in EEG manufacturing and distribution. With an aim to further increase market penetration, the company endeavors to integrate its EEG solution with existing telemedicine platforms to serve the direct neurology market in addition to bundling its diagnostic solutions with products in related sectors to service complimentary markets.

The first phase of the company’s three-stage development process was completed in 2019 with the creation of the NeuroCap and NeuroEEG devices. Currently in its second development phase, Brain Scientific is now focused on the creation of secure cloud-based infrastructure to transmit data between neurologists and patients. The final phase, scheduled for late 2021 and 2022, will focus on the development of AI and ML functionality to provide predictive analytics that increases the diagnostic capabilities offered by its devices.

Brain Scientific’s NeuroCap and NeuroEEG devices can be used to record EEGs in settings of all types such as neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. With patents already approved in the United States, Europe and China, the company is positioned to dominate the market for portable brain imaging devices to address the current neurologist shortfall, improve patient outcomes and expand its vision for telemedicine in the neurology industry.

For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Flora Growth Corp. is a Colombian cannabis cultivator that is building a global cannabis CPG portfolio of premium brands and products
• Flora Growth recently announced an LOI designed to grant it an in-road to Australia’s over-the-counter medical cannabis and CBD commercial markets
• The company also signed an LOI to distribute popular Canadian pain topical brand KaLaya throughout Latin American countries, with exports planned to the United States, and to infuse its established line of products with CBD
• Market analysts predict Australia’s medial cannabis market will explode from about $150 million this year to more than a billion dollars by 2025

The Colombia-based operations of cannabis cultivator, global brand builder and product distributor Flora Growth (NASDAQ: FLGC) are receiving increased attention from market watchers, particularly in the wake of the company’s announcement that it executed a letter of intent (“LOI”) with Australia’s Evergreen Pharmacare Pty Ltd. to supply medical-grade dried flower and derivative cannabis products to Australians through Evergreen’s pharmacy distribution network.

A July 27 statement issued by Flora Growth indicated Evergreen helps patients and healthcare practitioners, primarily physicians and pharmacists, obtain medical cannabis products and provides them with additional cannabis-related education about its use, authorization and regulation. Flora Growth will begin shipping its medical-grade cannabis products as soon as it harvests its first commercial crop and secures the necessary export licenses (https://cnw.fm/YefTQ).

Market analysts at FreshLeaf Analytics (https://cnw.fm/ValZP) and Prohibition Partners (https://cnw.fm/Ob8Ab) predict the medical cannabis segment will range in value from about US$150 million this year to up to US$1.5 billion by 2025, and the LOI between Flora Growth and Evergreen positions the Colombian grower (with headquarters in Miami, Florida) at the leading edge of a burgeoning market.

“This agreement also provides significant potential upside by allowing us to work with Australian regulators directly and bring our premium brands and established product formulations to the over-the-counter CBD market,” Chief Revenue Officer Jason Warnock stated in the company’s news release, adding that Australian regulators’ recent decision to down-schedule cannabidiol (“CBD”) to a level where it can be sold as an over-the-counter product opens the door to Flora’s strategy for “providing proven cannabinoid wellness and beauty products to consumers around the world.”

Flora Growth also recently announced that it has signed an LOI to form a joint venture with Canadian-based Avaria Inc., which manufactures pain cream under its flagship brand KaLaya. KaLaya is distributed nationwide across Canada and anticipates distribution across Latin American countries under the JV, with exports to the United States as Flora Growth manages registration, sales and distribution needs. The upside here is not only bringing these well-received products to international markets, but to also infuse these products with cannabinoids, particularly CBD, in order to generate incremental revenue.

Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale, so the partnership would see Flora Growth’s lab division providing it with a necessary boost to expand its market reach as it supplies the cannabis derivative products and low-cost manufacturing locally in Colombia.

In Canada, KaLaya has been recognized as the most popular topical analgesic brand distributed through Canadian retailer Purity Life and by The Shopping Channel in 2020, weighing in as Canada’s fastest growing topical decongestants and analgesics brand, according to Nielsen Market Track.

“Given CBD’s association with wellness, KaLaya’s established formulation, and Flora Growth’s low-cost high-quality cannabis, this is a natural partnership we are excited to bring globally,” Flora Growth President and CEO Luis Merchan stated in the news release.

For more information, visit the company’s website at www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

If you’ve ever had to jump-start a gas-powered car, then you know it’s a pretty straightforward process: find a car that’s still running, hook a couple of jumper cables from the functioning battery to the dead one and start the other car. But for electric vehicles (“EVs”), which run on rechargeable lithium-ion battery packs rather than an internal combustion engine, the process is a little different.

While it is common knowledge that electric vehicles rely on a high-voltage battery pack for their power needs, not everyone knows that EVs also have an additional 12-volt battery similar to the one under the hood of a conventional vehicle. And just like with petrol and diesel-powered cars, your EV will be unable to start if this battery loses charge.

Save for a few safety concerns due to the nature of an EV, jump-starting your electric car is quite simple as well. For starters, never attempt to jump-start the high-voltage lithium-ion battery that provides power to your vehicle’s electric motor. Additionally, you cannot use one EV to jump-start another vehicle. In an article for Kelly Blue Book, Chris Hardesty says that an electric vehicle’s charging points are only designed to jump-start the car itself, not give another vehicle juice.

Finally, make sure the vehicle you use to jump-start the dead car has a 12-volt battery equipped with a negative grounding system, such as the ones found in gas-powered vehicles.

Now that that’s out of the way, let’s take a look at what you have to do to get your EV’s 12-volt battery going again. First, position the two vehicles so that their batteries are close together but the cars aren’t touching. Engage the parking brakes, and ensure every light and accessory in both vehicles is turned off.

Now take out your jumper cables, clamp one end of the red positive cable (+) to the dead battery’s positive terminal and the other end of the positive cable to the good battery’s positive terminal. Then clamp one end of the black negative cable (-) to the negative terminal of the good battery and the other end to the dead battery’s grounding point. Check that the clamps have solid metal-to-metal contact with the charging points and battery terminals, and ensure that the cables are away from both vehicles’ moving parts.

Once you have confirmed that the clamps have good contact and the cables are clear and won’t get snagged by moving parts, start the car with the good battery. This should be enough to jump-start your EV’s 12-volt battery, and you can now start it.

As the EV models brought to market by various sector players such as Net Element (NASDAQ: NETE) become more common, motorists will have access to a growing amount of information regarding how to maintain their electric vehicles.

NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

A mine located in Bosnia and Herzegovina may soon resume silver production, after a more than three-decade hiatus, following years of civil unrest. Paul Cronin, CEO of Adriatic Metals Plc, which is the mining company that will be handling this project dubbed the Vares project, reveals that the silver mine could begin production by next year’s end. This is part of an emerging trend that involves resuming operations in “zombie” mines that halted production due to various reasons including political unrest, owner bankruptcy or weak prices.

In an interview, Cronin, a former investment banker, stated that some of these mines, which were abandoned and are scattered across the globe, created potential environmental issues that need to be addressed. He explained that converting these unused and dumped mines into something that added value would help resolve some of these issues and allow shareholders to gain returns from them.

Over the last year, the price of silver has increased by roughly 40%, and this trend is set to continue given the metal’s use in electric vehicle charging stations and solar panels. This rise in demand for precious metals will be observed across the board. Mining companies from South Africa and Australia to Europe are being driven by the commodities price rally, which is influenced by the infrastructure spending associated with the clean energy transition and global economic recovery.

For instance, Anglo American Platinum Ltd., the largest platinum company globally in terms of market value, was recently approached by no less than three different groups regarding its Bokoni mine, which has been idle for quite some time. Cronin stated that by recycling old mines, companies could reduce their costs through the use of the existing infrastructure. This includes mines that haven’t been in production for more than three decades. He cited the example of the Vares project, which already had roads and rail links in place, noting that the company was using some of the site’s existing facilities.

Incorporating new technologies to already existing sites could also make these operations more economically viable. For example, Adriatic Metals is working to develop a zinc project in Siberia. Other mining companies getting involved with restarting operations at these mines include Mincor Resources and Panoramic Resources Ltd. Both companies are resuming production at their nickel operations after putting them on care and maintenance in 2016 following weak international prices.

In a feasibility study, Boss Energy Ltd. also revealed that its Honeymoon mine, which holds uranium and was closed in 2014 in response to weak prices, may resume operations in about 12 months.

The growing interest in zombie mines is a clear sign to mining industry players such as Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) that the foreseeable future is bright as metals prices are likely to remain steady or even rise.

NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at  https://ibn.fm/EXN

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Summary

After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. According to US marketing research firm Frost-Sullivan, AnPac Bio ranked top three globally in terms of clinical and commercial test sample numbers in the space of new cancer detection technologies in 2019. In the next five years, AnPac Bio strives to become a global leader in early cancer screening, continuing to make meaningful contributions to the global cancer prevention cause.

Lead: 

As early as 2010, AnPac Bio proposed a pan- (multiple) cancer screening theory and method to change the way science and medical professional perform cancer tests. The hope was to help cancer testing become cheaper, faster, earlier, and cover more cancer types in one test. Some of Anpac’s issued patents in the US and China dated original ideas as early as 2010s1-3, and clinical study data were collected and available as well in that same period.  By 2014, it had already publicly announced its cancer detection product capable of detecting 16 types of cancer, which was much earlier than other company in the market.

The medical industry was perhaps not ready, and many doubted if pan cancer screening could even be a possibly.  Some called AnPac Bio’s pan cancer idea and clinical data “too good to be true”.  Cancer experts had different opinions on this concept.  Some of them believed that cancer should be screened one by one, because some reasoned, after all, each cancer type is different. Some experts further believed that some cancer types are not even suited for blood tests such as brain tumors and esophageal cancer.  Contrary to accepted opinions, AnPac Bio believed in its groundbreaking idea and innovation, forged ahead and persisted in proving out its Cancer Differentiation Analysis platform.

Dr. Chris Yu, Chairman and CEO of ANPC stated, “In the past ten years, AnPac Bio has spared no effort in pioneering this concept, even though we were doubted and laughed at by some people in the field. Our hard work to validate and promote the approach includes numerous retrospective clinical trials with many hospitals (no fewer than two), prospective and follow-up studies, significant applied and published patent applications involving pan-cancer screening claims in multiple countries, various publications at technical conferences including ASCO in the US4-7, and news releases. At the same time, with the active promotion and progress of peer companies in the field, and extensive data validating this concept first by AnPac Bio (Anpac Bio published at 2015 ASCO) and later by other companies, the innovative theory of pan-cancer screening was finally accepted by most of the industry over the last few years. Although groundbreaking innovation is often lonely and hard, we must always believe in ourselves and perseverance.”

Dr. Chris Yu’s highly successful career included significant research work at three US Fortune 500 company and other publicly listed high tech companies, through cross-disciplinary and break through innovations. He has significantly changed the IP and technology landscape and made profound impact on the long term roadmap in at least two areas in which he has worked. He has been a co-founder or founding executive member of three publicly listed high tech companies (including two companies on the NASDAQ and one company on the Science and Technology Innovation Board of the Shanghai Stock Exchange). He is an inventor of over 300 patent applications in about 20 countries and regions around the world, of which nearly 200 have been granted. He has repeatedly developed cross-disciplinary innovation ideas and successfully commercialized winning products based on those ideas, with a global revenue exceeding USD $4 billion.

Dr. Yu was born in a medical family and studied at Shanghai Second Medical College (now Shanghai Jiao Tong University School of Medicine). However, he was diagnosed with partial color blindness and had to switch his major to physics. After receiving a PhD degree in physics (with a PhD thesis on a novel detection technology for weak signal detection and processing) from Pennsylvania State University, he worked at leading US semiconductor companies including Micron Technology and Motorola.  After returning to his hometown Shanghai, China, beginning in 2008, Dr. Yu began contemplating how physics, IC technologies, and his knowledge about signal detection and processing can be used for cancer detection. Dr. Yu believed that the measurement of biophysical properties could be combined with his extensive work experience in the semiconductor industry to design and fabricate novel and highly sensitive sensors. Therefore, the use of an innovative IC device with unique sensors for the detection of biophysical characteristics in blood in order to detect cancer earlier became the original development concept of AnPac Bio.

He and his co-inventor filed their first patent application in 2009, and co-founded AnPac Bio in 2010, looking to develop a cost-effective pan cancer detection technology.  Dr. Yu began to devote himself to the application of fusing the latest in semiconductor design and fabrication with the measurement of biophysical properties to detect cancer. Together with co-founder Professor Herbert Yu and R&D vice president Du Xuedong, he founded AnPac Bio to become one of the first companies to develop cancer screening by detecting biophysical properties.

In January 2020, AnPac Bio was listed on the US NASDAQ stock market. Based on 2020 full year and 2021 Q1 financial reports, AnPac Bio is now one of the fastest growing publicly traded companies in the field.

AnPac’s technology is around its proprietary “Cancer Differentiation Analysis”, or CDA test, which is based on the correlation between biophysical characteristics in the blood sample and cancer risk. This technology and emerging technologies such as CTC, ct-DNA and exosomes are called “next generation” cancer screening and detection technologies.

At the beginning of 2010s, AnPac Bio applied for pan-cancer detection patents and developed an important, novel sensor for detection. The company conducted clinical research with many medical institutions to collect a large number of clinical study samples (> 40,000 clinical samples).

In 2014, AnPac Bio announced that its technology is capable of detecting 16 types of cancer.  By 2015, the Company had published four papers at 2015 ASCO4-7, which included clinical study data on lung cancer, liver cancer, esophageal cancer, and colorectal cancer.

Other companies in the cancer screening space, including Grail8, and Thrive9, which is based on CancerSEEK technology originating at Johns Hopkins University, have also begun to establish pan-cancer tests.

The complete process of AnPac’s cancer detection technology involves using internally developed and fully automated equipment to detect the biophysical parameters in the blood, and then calculate data based on proprietary algorithms to assess the level of cancer risk.

The purpose of early cancer screening is for early detection, early diagnosis, and early treatment. Very often, at early cancer stage, there are no obvious symptoms, and the significance of early screening is to conduct a risk assessment when the subject has no obvious symptoms. Those who are assessed as having a high risk of cancer is advised to go to a medical institution for further examination, so that they can discover potential cancer earlier.

AnPac Bio detects the biophysical parameters in the blood. This technology has the advantages of detecting multiple cancer types at early stage, with a high sensitivity and specificity, and at a lower cost.

Presently, AnPac Bio’s CDA platform can test up to 24 types of cancer in men and 26 types of cancer in women at one time, and the types of cancers detected are increasing. In addition to screening cancer patients, based on the follow-up data of more than 14,000 subjects, AnPac Bio’s detection technology has also detected a large number of patients with precancerous lesions. “This shows that our technology can also identify pre-cancer diseases and risk.” Dr. Yu stated.

“Before, there are many cancer types that cannot be easily detected and screened, and they have no known- bio-markers, however, our CDA technology can be used for preliminary screening. We fill the technological gap in this area. For example, with esophageal cancer and brain tumor, there are currently no established bio-markers available. The traditional method of esophageal cancer detection is endoscopy, but AnPac Bio’s technology can use blood to screen for esophageal cancer.” Dr. Yu continued.

Since its founding, AnPac Bio has firmly established the direction of independent research and development for the application of biophysics in high-throughput pan-cancer screening. The use of proprietary equipment has resulted in huge advantages in operating costs and company growth. In 2020, under a global health pandemic, cancer screening industry was greatly affected. However, revenue of AnPac Bio increased by 89% year-over-year, and its loss decreased by 20% year-over-year, which put AnPac Bio at one of the best performing companies (in terms of revenue growth and net loss decrease) in the field.  This significant advantage is expected to continue.

The higher rate of revenue growth over its publicly traded peers by AnPac Bio indicates that its technology and products are gaining increased market acceptance and market share.

Early cancer screening is an area that requires long-term investment. At present, the early cancer screening industry still faces many challenges. In addition to the need to continuously improve detection sensitivity and specificity, the difficulties include reducing detection costs and enhance market acceptance. AnPac Bio is well prepared to meet the above stated challenges, with its low cost structure, pan cancer screening strategy, and improving cancer detection sensitivity and specificity with further optimized algorithm (with increased larger data set) and new generation of sensors.

AnPac Bio recently announced completion of research and development, and validation of a new generation of sensors. “The design and process flow of the chip has been further optimized, which resulted in sensor device yield increase, and significant improvement in detection signal stability.” Dr. Yu said.

Normally, if a subject is assessed to be at high risk after an early cancer screening through a CDA test, the next step may be further testing and diagnosis in the hospital, and then cancer treatment. Cancer treatment is of course a crucial area in the medical field. For AnPac Bio, it may also be an extension of the company’s core technology which includes its expertise in biophysics and IC design and fabrication, as well as its deep understanding on what and how biophysical properties may have played a role in cancer evolution, and how biophysical signals change as the disease evolution is taking place.

“We have collected a significant amount of clinical data and found that as the condition of the potential cancer patients develops, biophysical indicators also change in a statistically significant way. We believe that the changes in biophysical indicators are related to the progression of the disease,” said Dr. Yu.

“Research by other groups have also found that changes in the micro-environment may lead to increased genetic mutations and cell division errors, which may further lead to diseases, including cancer. We are trying to explore whether we can use biophysical intervention and treatment methods to control diseases and prevent it from progression, or even directly reverse the process. Physical or Biophysical treatment technologies have already been successfully applied in certain cancer therapeutic fields, and AnPac Bio is also confident in attempting to develop our own novel technology in this area.”

The Company has continued to make progress towards its goals in 2021. On January 25, China’s National Medical Products Administration (NMPA) approved AnPac Bio to start the registration and testing of its Class III lung cancer auxiliary diagnostic medical devices in its designated medical device testing laboratory.

In late May, AnPac Bio announced that it would develop innovative cancer treatment technologies based on a biophysical approach. It is expected that the new technology will use key therapeutic modules manufactured by IC technology to intervene and treat cancer patients who exhibit abnormal biophysical characteristics. This project is expected to begin laboratory tests in the third quarter of 2021.

AnPac Bio continues to make tangible contributions to the cause of cancer prevention via its efforts in groundbreaking novel ideas, and develop them into cost effective products and services to benefit society as a whole. “We hope that in the future, AnPac Bio will become a role model of science and technology, as well as innovation.” Dr Yu stated.

References

(1)      US Patent# 9,408,565.

(2)      US Patent# 9,689,863.

(3)      Chinese Patent# CN 103608682 B.

(4)      Y. Zhang, et al., Abstract# e12578, J Clin Oncol 33, 2015.

(5)      J. Ji, et al., Abstract# e22171, J Clin Oncol 33, 2015.

(6)      X. Du, et al., Abstract# e12587, J Clin Oncol 33, 2015.

(7)      G. X. Jiang, et al., Abstract# e15059, J Clin Oncol 33, 2015.

(8)      GRAIL Press Release https://grail.com/press-releases/grail-announces-positive-new-data-with-multi-cancer-early-detection-blood-test-from-ccga-study/

(9)      J.D. Cohen, et al., Science 10.1126/science.aar3247(2018)

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Third-Party Content

The BMW website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the BMW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of BMW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and BMW does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by BMW providing you with this internet portal that makes accessible to you the ability to view third party content through the BMW site, BMW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. BMW expressly disclaims liability relating to such third-party content. BMW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, BMW reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.biomedwire.com/disclaimer.

• AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
• The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
• CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
• The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
• The global cancer diagnostics market is expected to reach $249.6 billion by 2026

AnPac Bio-Medical Science Co. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (“CDA”)

Cancer Differentiation Analysis (“CDA”) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

• Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
• Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
• Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
• Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
• Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
• Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://ibn.fm/EMdoS). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

For more information, visit the company’s website at www.AnPacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Senator Cory Booker has revealed that he and his Senate colleagues are in talks with the White House regarding cannabis legalization. Now that Senate Majority Leader Chuck Schumer, Senate Finance Committee Chairman Ron Wyden and Booker have released a discussion draft of a federal marijuana legalization bill, they are working to bring President Joe Biden on board. President Biden has said that while he supports modest cannabis reform, including medical marijuana and expunging low-level cannabis offenses from people records, he opposes broad reform.

The trio released the 163-page federal cannabis bill last month, asking the public for input so they could improve it before formally introducing it for legislation. Dubbed the Cannabis Administration and Opportunity ACT (“CAOA”), the legislation would deschedule cannabis at the federal level, expunge prior marijuana-related convictions and allow states to continue maintaining their own cannabis policies, among other things. When asked how he planned on soliciting Biden’s and Vice President Kamala Harris’s support during a Q&A session on Twitter, Booker said they will start conversations with the White House now that a discussion draft of their bill is out.

While cannabis reform advocates have praised the senators’ efforts to federally legalize cannabis, there is a chance Biden might veto the bill should Congress send it to his desk. Gaining his support, as hard as that may be given the president’s past as a “leading warrior in the drug war,” it increases the legislation’s odds of becoming law. However, the federal cannabis bill may not even reach the president’s desk, given how tenuous the Democrats’ hold on the Senate is.

The three Senators will have to drum up 60 votes in the Senate for the bill to pass, which seems unlikely at the momennt. Even with the Democrats’ slim majority over the GOP, some members of the party have raised concerns about the comprehensive federal cannabis bill. Some industry stakeholders believe that the Secure and Fair Enforcement (“SAFE”) Banking Act is much more likely to advance in the Senate because it has bipartisan support; however, Booker has ruled out moving it, stating that Congress first has to provide restorative justice for communities that were disproportionately affected by the drug war.

Additionally, he says that since the CAOA would federally deschedule cannabis, it would inadvertently resolve the banking issue. It would also offer a 50% tax reduction through a tax credit to small cannabis operators with less than $20 million in sales, he says.

The federal reclassification of cannabis is likely to boost the market for CBD products made by companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) since the controversy surrounding the plant may reduce and expose it to new markets and demographics.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The Global Market of Microreactors report centers on the potential of microreactors and the future international microreactor market, evaluating their potential deployment and unique capabilities in certain international markets in the period between 2030 and 2050. The report observes that the coming years will see a growing demand for nuclear microreactors in key markets around the world.

The study utilized various techniques to analyze rising market trends and rank markets in more than 60 nations, including newcomer countries and current users of nuclear energy in order to obtain various potential demands.

Microreactors are sometimes called nuclear batteries and are a subgroup of modular reactors with a capacity that ranges between 1 to 20 MWe. They include heat pipe reactors, molten salt reactors and light-water reactors.

The study included research conducted between 2019 and 2021, which focused on the possible applications for microreactors in the United States, Alaska and Puerto Rico’s federal facilities. These studies also included research conducted by Nuclear Alternative Project, a Puerto-Rican-led nonprofit organization that looked into the viability of the use of microreactors and small modular reactors in the provision of power to island territories such as Puerto Rico.

Research by scientists from the University of Wisconsin-Madison that defined the possible role of microreactors at government installations was also included, as well as research by the University of Alaska Anchorage that identified the economic development potential, applications and markets for nuclear-powered microreactors in the Arctic and Alaska plus its export potential for remote locations across the globe.

The report notes that the preliminary deployment of microreactors could help expand nuclear energy’s contribution in Western Europe and North America by the year 2030, adding that these areas would otherwise demonstrate minimal future growth with regard to nuclear energy. Deployments in the mid-term, which would begin by 2035, would see an expansion in Asia and Eastern Europe. Energy infrastructures are currently being developed in these regions.

In the long term, deployment in the period between 2040 and 2050 would be in big cities and urban markets that are vulnerable to climate change and lack access to energy. The report adds that to capture new market shares for microreactors, a balance between public acceptance, costs, technology performance and market demands must be achieved and some challenges defeated.

The report also notes that microreactors will not be in competition with centralized energy sources, even after they achieve deep penetration in key markets. Finally, the report highlights that some questions about microreactors, such as their transportation and fuel, as well as their physical and cyber risks, will have to be answered. Technical exchanges and collaborations, which include efforts by U.S. federal programs and efforts by Canadian and U.S. regulators, are focused on these priorities.

This bullish outlook for nuclear microreactors bodes well for uranium mining companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) since these companies will have a much bigger market to serve in the coming decades.

NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.